HR 6977119th CongressIn Committee

Better Care for PFAS Patients Act of 2026

Standard Summary
Balanced plain-English summary

The Better Care for PFAS Patients Act of 2026 directs the Agency for Toxic Substances and Disease Registry to arrange periodic assessments of PFAS health effects and clinical recommendations. It requires up-to-date clinical guidance for health care professionals and public health authorities, with updates at least every five years and consultation with PFAS-exposed communities.

Key Points

  • 1Requires ATSDR to enter an agreement with the National Academies or another appropriate entity within 60 days.
  • 2Directs an initial assessment of PFAS health effects measurable in human tissues and clinical recommendations within two years.
  • 3Requires updates at least every five years or more often if science warrants.
  • 4Requires ATSDR to issue, post, and disseminate clinical guidance to state and local public health authorities and health care professionals.
  • 5Requires consultation with PFAS-exposed communities about exposure, testing, and clinical follow-up experiences.

Impact Areas

PFAS-exposed communitiesHealth care professionalsState and local public health authoritiesAgency for Toxic Substances and Disease RegistryNational Academies of Sciences, Engineering, and Medicine
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026